**Core Concept**
Esmolol is a short-acting beta-1 selective adrenergic receptor blocker used in the management of tachyarrhythmias, hypertension, and perioperative tachycardia. Its pharmacokinetic profile allows for rapid onset and offset of action, making it suitable for acute settings.

**Why the Correct Answer is Right**
Esmolol's short duration of action is primarily due to its rapid hydrolysis by red blood cell esterases, particularly by the enzyme red blood cell acetylcholinesterase. This enzymatic degradation results in a rapid decrease in esmolol's plasma concentration, leading to a short half-life of approximately 9 minutes. This property enables healthcare providers to rapidly titrate esmolol's effects in response to changing clinical conditions.

**Why Each Wrong Option is Incorrect**
**Option A:** This choice is incorrect as esmolol's mechanism of action is not primarily due to its lipophilicity, which would not explain its rapid metabolism or short duration of action.

**Option B:** This option is incorrect as esmolol's beta-1 selectivity does not contribute to its short duration of action. Beta-1 selectivity is beneficial in minimizing peripheral effects, but it does not influence the drug's pharmacokinetics.

**Option C:** This choice is incorrect as esmolol's short duration of action is not due to its high clearance rate. While esmolol does have a high clearance rate, this is a consequence of its rapid hydrolysis, not the primary cause of its short duration of action.

**Clinical Pearl / High-Yield Fact**
Esmolol's rapid onset and offset of action make it an ideal choice for managing perioperative tachycardia, particularly in patients undergoing non-cardiac surgery. It allows for rapid titration and minimal impact on peripheral circulation.

**Correct Answer:** C. Its rapid hydrolysis by red blood cell esterases is the primary reason for esmolol's short duration of action.